Opko Health (NASDAQ: OPK)
Key Data Points
Opko Health Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Opko Health Company Info
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
News & Analysis
Why Shares of Opko Health Jumped on Thursday
The FDA approved a growth therapy the company was collaborating on with Pfizer.
Why OPKO Health Shares Jumped on Wednesday
A major pharma name is showing interest in one of the company's vaccine prospects.
Why Opko Health Stock Was a Surprise Winner This Week
Investors shrugged off the company's notably worse-than-expected quarterly results.
Why Opko Health Stock Is Jumping Today
The company topped Q1 revenue estimates and announced a key new acquisition.
Why Opko Health Stock Dipped on Friday
A bottom-line earnings miss adds to a general bearishness on coronavirus stocks.
Why Opko Health Stock Is Crashing This Week
The FDA refused to approve human growth hormone somatrogon.
Why Opko Health Stock Is Off 23% Today
The market was counting on a key drug approval that suddenly appears unlikely to happen.
Why Opko Health Shares Shriveled by Nearly 8% on Friday
The coronavirus stock didn't impress with its Q2 results.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.